-- 瑞银证券周一在一份报告中指出，孩之宝（Hasbro，股票代码：HAS）第一季度的业绩将主要取决于旗下威世智（Wizards of the Coast）部门的强劲需求，以及该公司如何将树脂和运费上涨的影响纳入损益表。 瑞银表示，威世智的需求强劲主要得益于《忍者神龟》（Teenage Mutant Ninja Turtles）和《史崔克斯海文的秘密》（Secrets of Strixhaven）在第一季度强劲的预售表现。 瑞银指出，鉴于树脂价格上涨以及运费和分销成本的增加，预计孩之宝将更加关注利润率。瑞银还表示，树脂成本每上涨10%，每股收益将增加约0.08美元；而进出境运费每上涨10%，孩之宝的每股收益将增加约0.09美元。 瑞银补充道，即使面临轻微的供应链中断，预计孩之宝仍将维持其2026年的营收预期。 瑞银维持买入评级，目标价为110美元。
Price: $95.34, Change: $-1.81, Percent Change: -1.86%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.